Overview

F01 in the Treatment of Autoimmune Diseases

Status:
RECRUITING
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open lable clinical study to evaluate the safety and tolerability of F01 in autoimmune diseases.
Phase:
PHASE1
Details
Lead Sponsor:
RenJi Hospital
Collaborator:
Shanghai Simnova Biotechnology Co.,Ltd.
Treatments:
Cyclophosphamide
fludarabine